MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$1,272K
Proceeds from issuance of
common stock and common...
$424K
Cash provided by
(used in) financing...
$1,696K
Net decrease in
cash, cash...
-$5,902K
Canceled cashflow
$1,696K
Acquired in-process
research and development
$19,927K
Accrued expenses and
other liabilities
$405K
Non-cash lease expense
$292K
Stock-based compensation
expense
$226K
Depreciation expense
$60K
Cash used in
operating activities
-$7,598K
Canceled cashflow
$20,910K
Net loss
-$27,696K
Accounts payable
-$454K
Operating lease
liabilities
-$287K
Prepaid expenses and
other assets
$71K
Back
Back
Cash Flow
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)
source: myfinsight.com